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Summary
Hereditary multiple exostoses (EXT; MIM 133700) is
an autosomal dominant bone disorder characterized by
the presence of multiple benign cartilage-capped tumors
(exostoses). Besides suffering complications caused by
the pressure of these exostoses on the surrounding tis-
sues, EXT patients are at an increased risk for malignant
chondrosarcoma, which may develop from an exostosis.
EXT is genetically heterogeneous, and three loci have
been identified so far: EXT1, on chromosome 8q23-q24;
EXT2, on 11p11-p12; and EXT3, on the short arm of
chromosome 19. The EXT1 and EXT2 genes were
cloned recently, and they were shown to be homologous.
We have now analyzed the EXT1 and EXT2 genes, in
26 EXT families originating from nine countries, to iden-
tify the underlying disease-causing mutation. Of the 26
families, 10 families had an EXT1 mutation, and 10 had
an EXT2 mutation. Twelve of these mutations have
never been described before. In addition, we have re-
viewed all EXT1 and EXT2 mutations reported so far,
to determine the nature, frequency, and distribution of
mutations that cause EXT. From this analysis, we con-
clude that mutations in either the EXT1 or the EXT2
gene are responsible for the majority of EXT cases.Most
of the mutations in EXT1 and EXT2 cause premature
termination of the EXT proteins, whereas missense mu-
tations are rare. The development is thus mainly due to
loss of function of the EXT genes, consistent with the
hypothesis that the EXT genes have a tumor- suppressor
function.
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Introduction
The multiple exostoses (EXT) gene family comprises five
homologous genes, including EXT1 (Ahn et al. 1995),
EXT2 (Stickens et al. 1996; Wuyts et al. 1996), EXTL1
(Wise et al. 1997), EXTL2 (Wuyts et al. 1997), and
EXTL3 (Van Hul et al., in press). Two of these genes,
EXT1 and EXT2, have been shown to be involved in
the pathogenesis of EXT, as they harbor germline mu-
tations in EXT patients (Ahn et al. 1995; Stickens et al.
1996; Wuyts et al. 1996). EXT is an autosomal domi-
nant condition with an incidence of ∼1/50,000. EXT
patients show multiple benign bony outgrowths (exos-
toses), typically located at the juxtaepiphyseal regions
of bones, that develop by enchondral bone formation
(Solomon 1964; Hennekam 1991; Schmale et al. 1994).
The presence of these bony outgrowths may cause pres-
sure on neighboring tissues, nerves, or blood vessels
(Hennekam 1991). The most severe complication is the
transformation of an exostosis into a malignant chon-
drosarcoma, although this complication is observed in
only 2%–5% of EXT patients (Solomon 1964; Hen-
nekam 1991; Schmale et al. 1994).
EXT is a genetically heterogeneous disease. In addi-
tion to the EXT1 gene on chromosome 8q23-q24 (Cook
et al. 1993) and the EXT2 gene on 11p11-p12 (Wu et
al. 1994; Wuyts et al. 1995), linkage analysis has indi-
cated the existence of a third gene (EXT3), on chro-
mosome 19p (Le Merrer et al. 1994). However, most
EXT families appear to be linked to the EXT1 and EXT2
loci (Cook et al. 1993; Blanton et al. 1996; Legeai-Mallet
et al. 1997).
The EXT1 and EXT2 genes are ubiquitously ex-
pressed, and they encode proteins of 746 and 718 amino
acids, respectively, that show homology to each other,
especially at the carboxy terminus (Stickens et al. 1996;
Wuyts et al. 1996). Both genes probably have a tumor
suppressor function, as chondrosarcomas show loss of
heterozygosity in both the EXT1 region on chromosome
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Table 1
Summary of EXT Families Analyzed
Family No. of Patients Country of Origin Mutationa EXT1 or EXT2a
1 16 Belgium C514T EXT2
2 8 Belgium 11731GrA EXT2
3 1 Morocco 11731GrT EXT2
4 2 Morocco U U
5 17 The Netherlands U EXT2b
7 1 Belgium 1469delT EXT1
10 1 Belgium U U
14 4 Italy C67T EXT2
15 3 Belgium 1679–1680insC EXT1
19 2 Germany 20682del6 EXT1
24 2 Belgium U U
26 2 Italy G204A EXT1
27 5 Belgium A838G EXT1
28 3 Turkey C1376G EXT1
29 5 The Netherlands 11731GrA EXT2
31 1 Belgium G600A EXT1
32 2 The Netherlands U U
35 1 The Netherlands 624ins5 EXT1
39 1 Belgium C1018A EXT1
40 1 Belgium U U
42 2 The Netherlands 11731GrA EXT2
49 1 France C514T EXT2
60 1 Great Britain 812–814delC EXT2
64 1 Italy G599A EXT1
70 4 USA 1263insAT EXT2
71 5 USA 649–652delT EXT2
a U  unknown.
b Based on linkage analysis (Wu et al. 1994).
8 and the EXT2 region on chromosome 11 (Hecht et
al. 1995, 1997; Raskind et al. 1995). Furthermore, an
inactivating somatic EXT1 mutation in a chondrosar-
coma has been reported (Hecht et al. 1997). Homology
searches of dbEST, with the EXT sequences used as
query sequences, identified three other genes that display
homology to the same carboxyterminal region. These
three EXT-like (EXTL) genes have been fully character-
ized by us and by others. EXTL1 maps to chromosome
1p36 (Wise et al. 1997), EXTL2 to 1p11-p12 (Wuyts et
al. 1997), and EXTL3 to 8p12-p22 (Van Hul et al., in
press), respectively. None of the EXTL genes has yet been
shown to be involved either in EXT or in any other
disease.
We have now performed a systematic mutation anal-
ysis of the EXT1 and EXT2 genes in EXT families, to
estimate the relative proportions of the EXT1 and EXT2
mutations and to study the spectrum and distribution
of mutations that lead to EXT.
Subjects, Material, and Methods
EXT Families
Twenty-six families with EXT, including 92 affected
patients originating from nine different countries, were
studied, to identify mutations in the EXT1 or the EXT2
gene. Seven of the 26 families have been described pre-
viously (table 1). Family 1, originating from Belgium,
was called “family 2” in the initial report describing the
localization of the EXT2 gene (Wu et al. 1994). This
family later contributed to the refinement of the EXT2
candidate locus and to the final identification of the
EXT2 gene. In both of these reports, the family was
referred to as “family 1” (Wuyts et al. 1995, 1996).
Family 2, also from Belgium, was reported previously
in the paper describing the isolation of the EXT2 gene
(Wuyts et al. 1996). Family 5, from the Netherlands,
was called “family 1” by Wu et al. (1994). Family 14,
reported in an article by Mollica et al. (1984), exhibits
brachydactyly and anetoderma in some affected family
members. Family 42 was reported previously as “family
3” (Wuyts et al. 1995). Families 70 and 71 are reported
as families “HME11” and “HME39” by Raskind et al.
(in press). The other 19 families have not been described
before (table 1). All EXT diagnoses were based on the
results of radiological examination.
Mutation Analysis
All exons of both the EXT1 and the EXT2 genes were
amplified separately by PCR; primers are listed in table
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Table 2
Primer Sequences Used
EXT1 PRIMERS EXT2 PRIMERS
Name Sequence
Length
(bp) Name Sequence
Length
(bp)
EXT1-ex1a CAGGCGGGAAGATGGCGGACTGG 212 EXT2-ex2a ctctcccctggtgacc 338
EXT1-ex1b CTCCGGCTGTGGCTCCTCGATGCCC EXT2-ex2A8 CACAGCGATAGACATCAAAACACG
EXT1-ex1c TGCTCTCAGCTGGCTCTTGTCTCG 201 EXT2-ex2A26 GACAGTCCCATCCCAGAGCGG 249
EXT1-ex1d GAATCCTCGTTTTCCAATTGATCCC EXT2-ex2A25 GGAGGGAACAAACAGACAGG
EXT1-ex1e CGGAGCCTCTGCGCCCCTTCGTTCC 232 EXT2-ex2A4 ACTACACTGATGACATCAACCG 176
EXT1-ex1f CTAGAATGTTTTGGTAACTTTCGGCG EXT2-ex2b ccctttagttccctgagggcc
EXT1-ex1g CGTATACCCACAGCAAAAAGGGG 209 EXT2-ex3a gttgacacattaattctccc 184
EXT1-ex1h CATTGTTCCACAAGTGGAGACTCTGC EXT2-ex3b gaacaaaaatgatcttgaaccc
EXT1-ex1i CCAGTTGTCACCTCAGTATGTGC 168 EXT2-ex4a gaataaagtcctttctttctcatcg 205
EXT1-ex1f2 GGCTTTGGCCAGCATCGCCAGG EXT2-ex4b cagtaaaggcacacctggc
EXT1-ex1k CCTGACTACACCGAGGACG 237 EXT2-ex5a gcaattttccaatcacctg 267
EXT1-ex1l GGTGTCTGATCCTATCCCTG EXT2-ex5b cctgagcctttgcgagagg
EXT1-ex1m GGTATTCAAGGGGAAGAGGTAC 231 EXT2-ex6a ctagtttgtaatctcttgcctc 222
EXT1-ex1j ggaccaaggccggcagagccc EXT2-ex6b tacgcagaaccactaatgtagag
EXT1-ex2a ccccacattcgcaatgagtc 225 EXT2-ex7a gggatgtggggctgaaggagg 293
EXT1-ex2b gagaggtgataatgttaaaccc EXT2-ex7b ctcctgtccctctgtatccagtc
EXT1-ex3a cgtattggaacagcttcgtctg 224 EXT2-ex8a gcttgctcacttaaaacagc 200
EXT1-ex3b gacgggggcagcaataatctgc EXT2-ex8b gcctcatgtggctagcac
EXT1-ex4a gtgcattctctttgttttacag 235 EXT2-ex8c ttatgctgcccttatcaggccc
EXT1-ex4b gctgagagaagtgtataaagg EXT2-ex9a cagctgcttttctgacccg 263
EXT1-ex5a cctttccaaatatcatcagg 237 EXT2-ex9b gatccagctgagagaggcac
EXT1-ex5b catcttcagggtaaacaagggc EXT2-ex10a cctcacaaaagttaggag 240
EXT1-ex5c ccattttgcaatgctctgctctg EXT2-ex10b aaacacactgtgtaaaacc
EXT1-ex6a gctttccagcgcttcattaggc 210 EXT2-ex11a gaatggttgctgtctgaattggg 235
EXT1-ex6b ctggagctggagcaggcagggg EXT2-ex11b ctcagttttgtcaccttgcc
EXT1-ex7a ggcgtacataaatacatcctacccc 189 EXT2-ex12a ccccttatttatcagctaaaggg 220
EXT1-ex7b ccaaggctccacagtggttcc EXT2-ex12b caagtgagtggcagagcc
EXT1-ex8a caagactctgaagttacctctttccc 204 EXT2-ex13a gtccttgacactgacagccagg 175
EXT1-ex8b ggtgactgcctgaacagcccacc EXT2-ex13b tagagatcagaggctaaggcgc
EXT1-ex9a cactgttgattgcttgtttggc 235 EXT2-ex14a caaacccctcctccccacctcctc 318
EXT1-ex9b gtaaagtctgtaagagacatgtcc EXT2-ex14c GTGGGTTAGGTGGGTGCATGCC
EXT1-ex10a cttgtcatcatgtgataatggccc 259 EXT2-M1 ccacctagagagctgggccatcgcat . . .
EXT1-ex10b gagtgaagcaaggaagaggg EXT2-M2 cagattgaagaaatgcagagccag
EXT1-ex11a ccttgcacttctctcatattatcc 230 EXT2-M3 catcccaagaatgaagaccaaggac
EXT1-ex11b CCTCAAAGTCGCTCAATGTCTCGG
EXT1-M1 gaatcctcgttttccaatggatc . . .
EXT1-M2 ggaatctggaaggacccaagccagc
NOTE.—Reverse primers are italicized, and modified nucleotides in modified primers are underlined. Primers located in introns are lowercased,
whereas primers located in exons are capitalized. The designation “ex” in each primer name is followed by the exon number. EXT2 primers
were designed from genomic sequences deposited in GenBank (accession numbers U67356–U67368).
2. Exon 1 of EXT1 and exons 2 and 14 of EXT2 were
split into several overlapping fragments, to obtain am-
plification products that did not exceed 350 bp. PCR
was performed in a 20-ml reaction volume, with a final
MgCl2 concentration of 1.5 mM. All PCR programs in-
cluded an initial denaturation of 4 min at 96C, followed
by 25–30 cycles of 30 s at 94C, 30 s at temperature
Tm, and 45 s at 72C. Finally, an extension at 72C was
performed for 5 min. Temperature Tm was 55C for all
primer combinations, with the exception of primers am-
plifying exons 7 and 8 of EXT1 and exons 3, 5, and 10
of EXT2. For these primer combinations, temperature
Tm was set at 51C. SSCP analysis of PCR fragments
was performed according to standard protocols. PCR
fragments that included aberrant fragments were ream-
plified and purified from agarose gels by use of the Se-
phaglas Bandprep kit (Pharmacia Biotech). Sequence
analysis, based on the dideoxy method, was performed
by means of dye terminator chemistry, with Taq poly-
merase. Sequencing reactions were composed of 25 cy-
cles of 30 s at 96C, 15 s at 52C, and 4 min at 60C.
After 25 cycles, the reaction products were quickly
chilled to 4C. All PCR products were sequenced directly
with one of the amplification primers. Sequences were
analyzed on ABI-373 and ABI-377 automatic sequencers
(Perkin-Elmer).
Mutations were confirmed by means of restriction
analysis, on the basis of creation or destruction of re-
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striction sites by the mutation. If necessary, modified
primers were designed to create restriction sites. All
modified primers used in this study are listed in table 2.
Restriction digestions were performed on PCR products
in accordance with standard protocols, and the restric-
tion fragments were separated on 3% agarose gels.
Results
We searched for mutations in the EXT1 and EXT2
genes in a set of 26 families with EXT.Mutation analysis
was performed by subjecting all exons to SSCP scanning
(primers are listed in table 2). All mutations were con-
firmed by means of restriction assay, sequence analysis,
or PAGE analysis. If more patients from the same family
were available, segregation of the mutation in the family
was confirmed by either restriction analysis or sequence
analysis. In the case of missense mutations, 50 healthy
control individuals were investigated, to exclude the pos-
sibility that the substitution was a polymorphism. Ten
different mutations were found in the EXT1 gene, and
seven different mutations were found in the EXT2 gene
(table 1). In six families, no mutation was detected, al-
though all exons of both the EXT1 and the EXT2 genes
were subjected to SSCP analysis.
EXT1 Mutations
The EXT1 gene consists of 11 exons, with a large
(1735 bp) first exon (Lu¨decke et al. 1997). Because the
sensitivity of SSCP analysis is known to decrease with
increasing fragment length, we analyzed this exon by
means of SSCP analysis of six separate overlapping frag-
ments, all !300 bp. Nucleotide numbering was based
on the sequence provided by Ahn et al. (1995), with
base 1 corresponding to the first base of the initiation
codon. Ten different EXT1 mutations were identified;
eight of these have not been reported previously.
Family 26.—The two patients in this Italian family
have a nonsense mutation, a substitution of G204 for
A in the first exon, that leads to a premature termination
of the protein after 67 amino acids. The G204A mu-
tation was confirmed by XhoII restriction digestion of
a 201-bp PCR-amplification product of primers EXT1-
M1 and EXT1-ex1c. The modified primer EXT1-M1
creates a XhoII restriction site (GGATCC) that allows
digestion in two bands, of 23 bp and 178 bp, respec-
tively, in the wild-type DNA. This restriction site has
been lost in the mutant allele.
Family 64.—The mutation in this Italian patient con-
sists of a de novo G599A transition, in the first exon,
that substitutes a stop codon for tryptophan 200. The
168-bp amplification product of primers EXT1-ex1i and
EXT1-ex1f2 is digested by HaeIII in bands of 111 bp,
49 bp, and 8 bp in controls. The G599A mutation de-
stroys one GGCC HaeIII site, resulting in two bands, of
160 bp and 8 bp, in patients carrying this mutation.
Family 31.—The one available patient from this Bel-
gian family has a G600A substitution, in exon 1, that
also terminates the EXT1 protein after 199 amino acids.
The G600A mutation was confirmed by restriction anal-
ysis, as described above for the G599A mutation (family
64).
Family 35.—In this Dutch family, the development of
EXT was shown to be caused by the duplication of five
nucleotides (TGGGG) following nucleotide 624, in exon
1, which causes a frameshift at F209. The mutation can
also be detected by PAGE of the 168-bp amplification
product obtained by means of PCR, with primers EXT1-
ex1i and EXT1-ex1f2.
Family 27.—In this Belgian family, which includes five
EXT patients, we identified an A838G mutation in exon
1. The same mutation has been reported by Raskind et
al. (in press) and results in an R280G substitution in the
EXT1 protein. The mutation can be detected by MspI
restriction digestion, as it creates a novelMspI restriction
site. The mutant 231-bp allele amplified with primers
EXT1-ex1m and EXT1-ex1j is digested in bands of 184
bp and 47 bp, respectively, whereas the wild type is not
digested.
Family 39.—The only available affected member of
this Belgian family has a C1018A mutation in exon 2
that results in an R340S substitution. This mutation has
never been reported before, but other missense muta-
tions that affect the same arginine at position 340 have
been reported previously in three other families (table
3). A modified PCR that uses primers EXT1-M2 and
EXT1-ex2a was developed. The 133-bp amplification
fragment is digested into fragments of 110 bp and 23
bp, by MspI restriction digestion, in the presence of the
C1018A mutation.
Family 28.—In this Turkish family that includes three
EXT patients, a C1376G mutation that substitutes a
stop codon for a serine at position 459 was identified
in exon 5. This mutation introduces a Sau3AI restriction
site (GATC), which allows mutation detection by PCR,
with primers EXT1-ex5a and EXT1-ex5b, followed by
Sau3AI restriction digestion. The normal band has a
length of 237 bp and is digested in bands of 148 bp and
89 bp, in the presence of the C1376G mutation.
Family 19.—A deletion of six nucleotides in the 5′
splice site of exon 5 (14172del6) was identified in the
two EXT patients in this German family. Although the
effect of the 14172del6 mutation on the EXT1 splicing
has not been studied, it is likely that the 5′ splice site of
intron 5 is destroyed. The 14172del6 mutation can
also be detected by PAGE of the PCR amplification prod-
uct obtained by PCR, with primers EXT1-ex5a and
EXT1-ex5b.
Family 7.—The only available affected member of this
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Table 3
Mutations Identified in the EXT1 Gene
cDNA Changea Exon or Intron Protein Changeb Type of Mutation Reference(s)
1 118delC Exon 1 FS H40 Frameshift Raskind et al. (in press)
2 174–176delC Exon 1 FS P59 Frameshift Philippe et al. (1997)
3 G204A Exon 1 W68X Nonsense Present study
4 242–247insC Exon 1 FS R83 Frameshift Wells et al. (1997)
5 248–249delG Exon 1 FS Q84 Frameshift Wells et al. (1997)
6 C357A Exon 1 Y119X Nonsense Raskind et al. (in press)
7 420ins4 Exon 1 FS S141 Frameshift Hecht et al. (1997)
8 527del8 Exon 1 FS K177 Frameshift Hecht et al. (1997)
9 G599A Exon 1 W200X Nonsense Present study
10 G600A Exon 1 W200X Nonsense Present study
11 624ins5 Exon 1 FS F209 Frameshift Present study
12 713delC Exon 1 FS S238 Frameshift Hecht et al. (1997)
(two families)
13 A838G Exon 1 R280G Missense Present study; Raskind
et al. (in press)
14 G840C Exon 1 R280S Missense Raskind et al. (in press)
15 G1016A Exon 2 G339D Missense Philippe et al. (1997)
16 C1018A Exon 2 R340S Missense Present study
17 C1018T Exon 2 R340C Missense Philippe et al. (1997)
18 G1019T Exon 2 R340L Missense Hecht et al. (1997)
19 G1019A Exon 2 R340H Missense Raskind et al. (in press)
20 10561GrA Intron 2 U Splice site Wells et al. (1997)
21 A1057-2G Intron 2 U Splice site Raskind et al. (in press)
22 1091–1093insGG Exon 3 FS E365 Frameshift Raskind et al. (in press)
23 G1122A Exon 3 W374X Nonsense Philippe et al. (1997)
24 1203–1204insC Exon 4 FS L402 Frameshift Raskind et al. (in press)
25 1215del4 Exon 4 FS R405 Frameshift Raskind et al. (in press)
26 C1376G Exon 5 S459X Nonsense Present study
27 14171GrA Intron 5 U Splice site Philippe et al. (1997)
28 14172del6 Intron 5 U Splice site Present study
29 1426–1431insC Exon 6 FS S478 Frameshift Hecht et al. (1997);
Raskind et al. (in
press)
30 1431insT Exon 6 FS S478 Frameshift Wells et al. (1997)
31 1469delT Exon 6 FS L490 Frameshift Present study; Ahn et
al. (1995) (two fami-
lies); Wells et al.
(1997); Philippe et al.
(1997) (two families)
32 1679–1680insC Exon 8 FS V561 Frameshift Present study
33 G1817A Exon 9 W606X Nonsense Wells et al. (1997)
34 1878del3 Exon 9 H627del 1 AA deletion Raskind et al. (in press)
35 C2053T Exon 10 Q685X Nonsense Raskind et al. (in press)
a All mutations were numbered uniformly; the adenosine of the start codon was assigned nucleotide position 1.
b U  unknown.
Belgian family has a 1469delT deletion in exon 6, which
causes a frameshift, with L490 being the first amino acid
substituted. The same mutation has already been re-
ported in six other families (table 3), and it can be con-
firmed byMvaI digestion of the PCR product of primers
EXT1-ex6a and EXT1-ex6b. In controls, this results in
digestion of the 210-bp amplification product, in three
fragments of 90 bp, 70 bp, and 50 bp, respectively. Pa-
tients who carry the 1469delT mutation have lost one
MvaI site, and they exhibit bands of 160 bp and 50 bp,
respectively.
Family 15.—Development of EXT in the three affected
members of this Belgian family was found to be caused
by the insertion of one cytosine in a triplet of cytosines
at nucleotide position 1678–1680 in exon 8. The 1678-
1680insC mutation causes a frameshift that starts at
V561.
EXT2 Mutations
The EXT2 gene consists of 15 exons (GenBank ac-
cession numbers U67354–U67368). Exons 1a and 1b
were not included in the mutation analysis, as they en-
code the 5′ UTR. Since exon 2 is 566 bp, it was analyzed
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by means of SSCP analysis of three overlapping frag-
ments. The nucleotide numbering of Wuyts et al. (1996)
was used, with position 1 given to the adenosine of
the start codon. We identified a mutation in the EXT2
gene in seven families. Four of these mutations have
never been described before.
Family 14.—This Italian family includes five EXT pa-
tients, all of whom have a C67T mutation that creates
a stop codon after 22 amino acids. A modified PCR,
with primers EXT2-A8 and EXT2-M3, was developed
to detect this mutation. The mutation destroys an AvaII
site created by the modified PCR, which results in the
inability of AvaII to cut the 249-bp fragment generated
by PCR. Controls exhibit a restriction pattern with two
bands, of 22 bp and 227 bp, respectively.
Family 49.—A C514T mutation that leads to a pre-
mature stop codon at amino acid 172 was identified in
a member of this French family. The same mutation was
found previously in the large Belgian family 1, and a
modified PCR to detect this mutation has been described
previously (Wuyts et al. 1996).
Family 71.—In this family from the United States, five
EXT patients have a deletion of one thymine in a stretch
of four thymines, at position 649-652, in exon 4. The
649-652delT deletion results in a frameshift, with the
serine at position 218 being the first amino acid
substituted.
Family 60.—In this English patient, we identified a
deletion of one cytosine in a triplet of cytosines, at po-
sition 812-814, in exon 5. The 812-814delC mutation
causes a frameshift, with A271 being the first amino acid
substituted.
Family 29.—A 11731GrA splice-site mutation, at
the 1 position of the 5′ splice site in intron 7, was
identified in this Dutch family, which includes five EXT
patients. To confirm the mutation, we amplified a 100-
bp fragment containing the 5′ splice site, with primers
EXT2-ex7a and EXT2-M2. The amplification product
was digested by ScrFI restriction enzyme. The wild-type
PCR fragment contains an ScrFI restriction site, whereas
the mutant allele has lost this site. Digestion of the am-
plification product results in fragments of 22 bp and 78
bp, respectively. This mutation was detected previously
in the Belgian family 2, and the mutation was shown to
cause skipping of exon 7, which leads to a truncated
protein (Wuyts et al. 1996).
Family 42.—The two available EXT patients from this
Dutch family also have the 11731GrA mutation.
Family 3.—The single EXT patient from this Mor-
occan family has a 11731GrT transition at the first
nucleotide of intron 7. This mutation can also be de-
tected by ScrFI digestion of the EXT2-ex7a and EXT2-
M2 amplification products, as described above for the
11731GrA mutation (family 29).
Family 70.—The four affected members of this Amer-
ican family have an insertion of two nucleotides at po-
sition 1263, in exon 8, which causes a frameshift; A422
is the first amino acid substituted. This 1263insAT mu-
tation can be detected by PAGE of the amplification
product of exon 8.
Discussion
We have analyzed 26 EXT families, from nine differ-
ent countries, for the presence of mutations in the EXT1
and EXT2 genes. For both genes, the intron-exon
boundaries have already been determined; this facilitates
large-scale mutation analysis at the genomic level. SSCP
analysis was chosen as the detection method because of
its simplicity and its high detection rate (80%–90%).
Ten families were found to have a mutation in the EXT1
gene, and another 10 families were found to have an
EXT2 mutation. In six families (23%), we did not detect
any mutation. This might be due to the shortcomings of
the SSCP screening method. Indeed, large rearrange-
ments (such as the large deletions or translocations, in-
volving the EXT genes, that have been described in the
past [Ahn et al. 1995; Lu¨decke et al. 1995; Stickens et
al. 1996]) or mutational events that result in failure to
anneal the primer are not detected by SSCP in a dom-
inant disease, because of the background of the wild-
type allele. Also, point mutations that do not cause
enough conformational differences during the renatur-
ation process are not detected. This is demonstrated by
the 11731GrA splice-site mutation in the EXT2 gene,
which was initially detected at the cDNA level (Wuyts
et al. 1996); in the present study, this mutation appeared
to be undetectable by SSCP analysis of genomic DNA.
Furthermore, we did not look for mutations either in
the 5′ and 3′ UTRs or in the promoter regions. Mutation
analysis of the open reading frame of EXT1 has been
unsuccessful in several families who demonstrated link-
age to the EXT1 locus; this suggests the existence of a
minority of mutations outside the EXT1 protein–coding
region (Hecht et al. 1997; Wells et al. 1997; Raskind et
al., in press). Of our six families without an aberration
detectable by SSCP, five were too small to allow us to
perform linkage analysis. Only family 5 was suitable for
linkage analysis, and this family was previously shown
to be linked to the EXT2 locus (Wu et al. 1994). Finally,
the majority of families that do not show an EXT1 or
an EXT2 aberration may have mutations in other EXT-
causing genes. In addition to the EXT3 gene on chro-
mosome 19, the recently identified EXTL1 (Wise et al.
1997), EXTL2 (Wuyts et al. 1997), and EXTL3 (Van
Hul et al., in press) genes may be interesting candidates
for mutation screening among EXT patients who have
neither an EXT1 nor an EXT2 mutation.
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Figure 1 Distribution of mutations in the EXT1 (A) and EXT2 (B) genes, reported in the present study or in previous studies. Mutations
are referred to by numbers, as in tables 3 and 4. Missense mutations are drawn above the schematic representation of the gene, and inactivating
mutations are drawn below. Black boxes represent coding regions. Exons have been numbered on the basis of both the genomic structure
provided by Lu¨decke et al. (1997) for EXT1 and the GenBank accession numbers (U67354–U67368) for EXT2.
EXT1 Mutations
Ten different mutations were identified in the EXT1
gene in our set of 26 EXT families; 8 of the 10 mutations
had not been reported before. Thirty-five different EXT1
mutations, summarized in table 3, have been reported,
to date. Seventy-seven percent of these mutations are
nonsense mutations, splice-site mutations, or frame-
shifts, which cause premature termination of the EXT1
protein. These truncated EXT1 proteins are probably
inactive, and it is likely that they degraded rapidly, re-
sulting in a nearly complete loss of function. Seven dif-
ferent missense mutations have been identified. Inter-
estingly, five of them substitute two adjacent amino
acids, G339 and R340. Sequence analysis revealed that
these amino acids define part of a potential proteolysis-
amidation site (x-G-[RK]-[RK]). Such amidation sites
are often found at the C termini of hormone precursors
and other active peptides, and they function as active
precursor cleavage sites. However, in the EXT1 protein,
the amidation site occurs in the middle of the protein,
and it seems unlikely that this site is functional. The
clustering of missense mutations in these two codons
may indicate that these two amino acids, G339 and
R340, are crucial for proper function or stability of the
EXT1 protein. Both of the other two missensemutations
affect arginine 280; this indicates that the R280 position
is also essential for functional activity or stability of the
EXT1 protein.
Thirty-five different mutations have been described in
43 families (table 1); this implies that most mutations
are private mutations that are present in only a single
family. However, one mutation, 1469delT, has already
been found in six different families, and it probably rep-
resents the most recurrent mutation in the EXT1 gene.
Analysis of the distribution of mutations over the EXT1
coding region indicates that the carboxyterminal part of
the EXT1 genes contains fewer mutations than expected.
The distribution of mutations in the EXT1 gene, in-
cluding those identified in this study and those identified
in previous studies, is displayed in figure 1A. Only 4
(11%) of the 35 reported EXT1 mutations are located
within the 250 carboxyterminal amino acids, which rep-
resent 34% of the EXT1 protein. All four of these mu-
tations cause premature termination of the protein, and,
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Table 4
Mutations Identified in the EXT2 Gene
cDNA Changea Exon or Intron Protein Change Type of Mutation Reference(s)
1 C67T Exon 2 Q23X Nonsense Present study
2 77–78insT Exon 2 FS Y26 Frameshift Philippe et al. (1997)
3 449del4 Exon 2 FS A150 Frameshift Stickens et al. (1996)
4 C514T Exon 2 Q172X Nonsense Present study; Wuyts
et al. (1996)
5 649–652delT Exon 4 FS S218 Frameshift Present study
6 C666G Exon 4 Y222X Nonsense Philippe et al. (1997)
7 G679A Exon 4 D227N Missense Philippe et al. (1997)
(two families)
8 812–814delC Exon 5 FS A271 Frameshift Present study
9 11731GrA Intron 7 FS R360 Splice site Present study (two
families); Wuyts et
al. (1996)
10 11731GrT Intron 7 FS R360 Splice site Present study
11 C1201T Exon 8 Q401X Nonsense Philippe et al. (1997)
12 1263insAT Exon 8 FS A422 Frameshift Present study
a All mutations were numbered uniformly; the adenosine of the start codon was assigned nucleotide position 1.
so far, no missense mutations have been identified in this
region. Interestingly, this region shows the highest degree
of conservation between the several members of the EXT
gene family (Van Hul et al., in press; Wuyts et al. 1997).
EXT2 Mutations
Seven different mutations were identified in the EXT2
gene in our set of 26 EXT families (table 1). Four of the
seven mutations have not been reported previously. Ta-
ble 4 summarizes the 12 different EXT2 mutations that
have been reported to date.
Family 2, from Belgium, is known to harbor a
11731GrA splice-site mutation that results in exon
skipping of exon 7 (Wuyts et al. 1996). We identified
the same mutation in families 29 and 42 (table 1). All
three families with the 11731GrA mutation originate
from Belgium or the Netherlands, two neighboring
countries, and we suspected that these three families
share a common ancestor. Therefore, we analyzed sev-
eral patients from these three families by means of poly-
morphic markers flanking the EXT2 gene, and a com-
mon disease haplotype was indeed found (data not
shown). This finding suggests that these families have a
common ancestor and that the 11731GrA mutation
most likely does not represent a recurrent mutation. The
distribution of mutations in the EXT2 gene, including
those identified in this study and those identified in pre-
vious studies, is displayed in figure 1B.
Relative Proportion of EXT1 to EXT2 Mutations
Previous estimates of the fractions of EXT cases
caused by mutations in EXT1 or in EXT2 were based
mainly on linkage studies of EXT families. Cook et al.
(1993) provided evidence of linkage to chromosome 8
in 7 of their 11 families. Blanton et al. (1996) mapped
6 of their 12 families to chromosome 8, and theymapped
the remaining 6 families to the EXT2 locus at chro-
mosome 11. A recent French study analyzed 29 smaller
families and assigned 8 (28%) of them to the EXT1
locus, 5 (17%) to the EXT2 locus, and 3 (10%) to the
EXT3 locus on chromosome 19p. However, most of the
families were too small to establish definite linkage with
one of the EXT loci (Legeai-Mallet et al. 1997). By
means of a combination of linkage analysis and muta-
tion analysis of EXT1, Raskind et al. (in press) deter-
mined that EXT1 is responsible for the development of
exostoses in 66% of the 34 EXT families they analyzed.
The present study represents the first study of a larger
group of EXT cases in which mutation analyses of both
the EXT1 and the EXT2 genes were performed. Of the
26 families examined in this study, 10 (38.5%) had an
EXT1 mutation, and 10 (38.5%) had an EXT2 muta-
tion. However, as the three EXT2 families with the
11731GrA mutation probably represent one large
family, the proportion of EXT1 to EXT2 mutations is
42% to 33%. Recently, Philippe et al. (1997) reported
mutations in 12 of 17 EXT families analyzed. Seven
(41%) of the mutations were found in the EXT1 gene,
and five (29%) were found in the EXT2 gene (Philippe
et al. 1997). All of these studies suggest that the majority
of mutations that cause EXT are located within the
EXT1 and EXT2 genes.
Given the significant number of mutations identified
in both the EXT1 and the EXT2 genes, it would be
interesting to examine whether phenotypic differences
can be observed in patients who harbor mutations in
either gene. Unfortunately, because detailed clinical data
were not available for all patients in our study, we were
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unable to investigate the presence or absence of a pos-
sible genotype-phenotype correlation for the EXT genes.
Inactivating mutations represent the vast majority of
mutations in both the EXT1 (77%) and EXT2 (92%)
genes, supporting the hypothesis that both EXT1 and
EXT2 have a tumor suppressor function that is lost dur-
ing the development of exostoses.
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